Boai NKY Medical Holdings Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Boai New Kaiyuan Medical Technology Group Co., Ltd. (referred to as New Kaiyuan NKY) is a Chinese ChiNext listed company with stock code 300109. The two major business segments of the company are precision medical and precision chemical. The precision medical business includes molecular diagnosis, pathological testing, and scientific research services based on gene sequencing as the main technology platform. In terms of fine chemicals, New Open Source is the world's third largest and Asia's largest manufacturer of polyvinyl pyrrolidone (PVP) series products, occupying an important position in the global industrial landscape. As a holding platform, New Kaiyuan has multiple subsidiaries, mainly including Boai New Kaiyuan Pharmaceutical Co., Ltd., Shanghai New Kaiyuan Precision Medical Co., Ltd., Wuhan He'er Medical Technology Development Co., Ltd., Changsha Sanji Biotechnology Co., Ltd., Jingneng Biotechnology (Shanghai) Co., Ltd., Suzhou Dongsheng Xingye Scientific Instrument Co., Ltd. Since its development in 2014, the new open source medical sector has been committed to the marketing strategy of focusing on tumor accompanied diagnosis, transforming advantageous technology products as the starting point, marketing channels as the leading force, and customer service as the concept of life. In response to the call of the "Healthy China Action", we provide convenient and high-quality tumor treatment accompanied diagnosis products and services to customers across the country. In recent years, New Open Source has continuously focused on the forefront of medical research and conducted extensive and in-depth layout, establishing three fulcrums in precision medical business: device side. New Open Source has independently developed SPICM-DNA type fully automatic cell tumor screening and analysis system, pyrophosphate analyzer, real-time fluorescence quantitative PCR detection system, etc; On the reagent side, the newly developed self-produced equipment is equipped with self-produced reagents. The company, relying on BioVision in the United States and Abcam in the UK, will further enhance its reagent products; Based on the first two technological fulcrums, New Open Source continues to develop and improve its third fulcrum - medical services. Every year, it provides screening, diagnosis, and post-treatment examinations for nearly one million Chinese people, including cancer and chronic diseases, and provides scientific research services to thousands of scientists, doctors, and research institutions. Since 2019, New Open Source has selected Songjiang District, known as the "Root of Shanghai", as its medical business management headquarters. It has also begun the construction of the "New Open Source Precision Medical Global R&D Transformation and Production (Shanghai) Base", which covers an area of 56 acres and has a total construction area of over 120000 square meters. The new base has been rated as a "municipal level biopharmaceutical major industry project" by the Shanghai Municipal Commission of Economy and Information Technology, and is expected to be completed within 2022 and put into operation in 2023. New Open Source has always been committed to process innovation and new product development, and has established the company's technology research and development center and Tianjin Polymer Application Research Institute to track global technological trends and effectively serve customer needs. The company's independent research and development achievements have filled the domestic gap, and in the chemical industry, it has obtained 16 invention patents and 21 utility model patent authorizations; Obtain 20 computer software copyright certificates; We have independently developed 16 proprietary technologies, many of which have reached advanced domestic or international levels; So far, 33 trademark registrations have been obtained. In the medical field, we have obtained 10 patents and 24 software copyrights. In recent years, New Open Source has been recognized as a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and its technology research and development center has been rated as a provincial enterprise technology center. It has won many honors such as provincial and municipal advanced enterprises in technological innovation, and exemplary organization in environmental protection. New Open Source is based on precision medical services and the production of health care products. With the concept of fraternity, we strive to improve technical quality, serve the general public, and create a better life. |
| Headquarter | Jiaozuo |
| Establish Date | 3/13/2003 |
| Listed Code | 300109.SZ |
| Listed Date | 8/25/2010 |
| Chairman | Zhang Junzheng. |
| CEO | Zhang Junzheng. |
| Website | www.nkygroup.cn,www.boai-nky.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
